Partial
Not Aligned
Patient Risk:
Moderate
Summary
Mechanism and some lipid/CV risk claims are supported by provided label excerpts, but multiple claims are unsupported or mischaracterized within the provided sections (notably HDL “excretion” and several adverse effect/timing assertions). Additionally, the evaluation cannot confirm key label domains (e.g., contraindications, boxed warnings, adverse reactions section 6, dosing/administration), so overall adherence is incomplete.
Category Scores
Accurate Statements
Lipitor (atorvastatin) is a statin.
Not supported by the provided excerpts (label sections provided do not explicitly call LIPITOR a “statin”).
Lipitor works by inhibiting the production of cholesterol in the liver.
Supported in substance: 12.1 states inhibition of HMG-CoA reductase and cholesterol synthesis in the liver and lowering plasma cholesterol.
Lipitor inhibits the enzyme HMG-CoA reductase responsible for producing cholesterol in the liver.
12.1 Mechanism of Action.
Lipitor reduces the amount of cholesterol produced in the liver.
12.1 indicates inhibition of cholesterol synthesis in the liver and lowering plasma cholesterol.
Lipitor increases the amount of LDL receptors on the surface of liver cells.
12.1 states increasing number of hepatic LDL receptors on the cell surface.
Lipitor increases the amount of HDL cholesterol in the bloodstream.
12.1 states variable increases in HDL-C and increases in HDL-C in isolated hypertriglyceridemia.
Lipitor lowers LDL cholesterol.
12.1 reduces LDL-C in multiple populations.
Lipitor increases HDL cholesterol.
12.1 (variable increases in HDL-C; increases in HDL-C).
Lipitor can reduce the risk of heart attack and stroke.
1.1 lists indications to reduce risk of myocardial infarction and reduce risk of stroke.
Lipitor can lower triglycerides.
12.1 states reduction of VLDL-C and TG and that LIPITOR reduces TG.
Unsupported Statements
Lipitor increases the amount of LDL receptors on the surface of liver cells.
Flagged as inaccurate: the statement is supported by 12.1; included above as accurate—no additional reason.
Increased LDL receptors on liver cells help remove excess cholesterol from the bloodstream.
Partially supported: 12.1 describes enhanced uptake and catabolism of LDL via LDL receptors, but the provided excerpt does not explicitly phrase “remove excess cholesterol from the bloodstream.”
Increased HDL cholesterol helps remove excess cholesterol from the bloodstream and transport it to the liver for excretion.
Not supported by the provided excerpts. 12.1 associates increased HDL-C with decreased cardiovascular risk but does not state HDL “removes excess cholesterol from the bloodstream” or “transport it to the liver for excretion.”
Lipitor can help to lower blood pressure.
No support in the provided label excerpts (12.1, 12.2, 1.1, 1.2, and 5.1–5.3 provided).
Common side effects of Lipitor include muscle pain and weakness.
Partially supported: 5.1 defines myopathy as muscle aches/weakness, but the excerpt does not establish these as “common side effects.”
Common side effects of Lipitor include memory loss and confusion.
Not supported by the provided excerpts.
Common side effects of Lipitor include diarrhea and abdominal pain.
Not supported by the provided excerpts.
Common side effects of Lipitor include headaches and fatigue.
Not supported by the provided excerpts.
Long-term use of Lipitor can increase the risk of developing type 2 diabetes.
Not supported by the provided excerpts.
Lipitor typically starts working within a few weeks of starting the medication.
Not supported by the provided excerpts (no onset/timing language in 12.1/1.x/5.x excerpts).
Lipitor may take several months to see the full benefits.
Not supported by the provided excerpts.
Contradictions
Important Omissions
FDA label domains not provided for evaluation: contraindications (4), boxed warnings status (if applicable), detailed warnings/precautions beyond skeletal muscle and liver dysfunction, drug interaction section (7), adverse reactions frequency and characterization (6), dosage/administration (2), and use in specific populations (8).
Importance:
High
Safety Assessment
Potential Patient Risk:
Moderate
Several safety-related claims in the extracted set (memory loss/confusion, diarrhea/abdominal pain, headaches/fatigue, increased type 2 diabetes risk) are unsupported by the provided excerpts, and key label safety domains (e.g., contraindications, adverse reactions section 6, boxed warnings, pregnancy/lactation) were not available in the evaluation inputs. This limits confidence in safety fidelity.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Not Aligned
Primary Issue
Multiple extracted claims are unsupported or only partially supported by the provided label excerpts, and critical safety label sections were not provided for evaluation.
Suggested Improvement
Re-evaluate using the full FDA label text for sections 2, 4, 5, 6, 7, and 8; restrict extracted claims to statements explicitly supported by those sections (including adverse reaction frequencies and timing of effects if present).